The PROMPT Study

Share
Print
Share
Print

To accelerate research and better manage care for people at risk for hereditary cancer, Memorial Sloan Kettering is collaborating with other academic research institutions and commercial laboratories to build the Prospective Registry of MultiPlex Testing (PROMPT). The PROMPT study began in 2016 and is expected to continue until 2022.

What gene mutations does the PROMPT study include?

The PROMPT study mainly focuses on non-BRCA and non-Lynch syndrome genes. Particular genes of interest include ATM, BARD1, BRIP1, CDH1, CHEK2, NBN, PALB2, RAD51C, RAD51D, and TP53.

The PROMPT registry collects data from individuals and their families whose multigene panel test results indicate that they carry mutations in one or more of these or other genes, and who have agreed to have their health status monitored.

By analyzing this information, doctors and researchers will be better able to study uncommon or rare gene variants. They will also be able to explore more effective ways to help these individuals and their families manage their risk for developing cancer.

What are the benefits of joining the PROMPT registry?

In addition to knowing that you are participating in a community that helps address these cancer research questions, as a PROMPT participant you will have access to curated research information and, in some cases, updates from the study coordinators on questions that may be of particular interest to you.

What is involved in joining the PROMPT registry?

We invite people who have had multiplex genetic testing and have a mutation in any non-BRCA and non-Lynch syndrome gene to register at www.promptstudy.info

Once you have registered, you will be asked to fill out questionnaires about your personal and family history of cancer.

How do I join the PROMPT registry?

For questions about participating in the PROMPT registry through MSK, contact us at medprompt@mskcc.org.